Skip to main content
. 2020 Jun 26;16(6):e1008522. doi: 10.1371/journal.ppat.1008522

Fig 7. Trial design, EV03/ANRS VAC20 Phase I/II Trial.

Fig 7

Schematic representation of EV03 study design: three injections of DNA (at weeks 0, 4 and 8) plus one NYVAC (at week 24) or two DNA (weeks 0, 4) plus two NYVAC (weeks 20, 24) were administered in 3xDNA and 2xDNA groups, respectively.